Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
FGFR1-4 tyrosine-kinase inhibitor

Futibatinib (Specialist drug)

Brand names: Lytgobi

Futibatinib is an oral fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor used to treat locally advanced or metastatic cholangiocarcinoma harbouring FGFR2 gene fusions or rearrangements.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a covalent, irreversible inhibitor of FGFR1-4, blocking aberrant FGFR signalling that drives proliferation in tumours with FGFR2 alterations.

Prescribing in practice

  • Hyperphosphataemia is an on-target class effect that can lead to soft-tissue mineralisation and retinal disorders, requiring phosphate monitoring and a phosphate-lowering strategy.
  • Use is restricted to tumours with confirmed FGFR2 fusions or rearrangements by validated testing, under specialist oncology supervision.
  • Retinal pigment epithelial detachment and other ocular effects can occur, so baseline and periodic ophthalmological assessment is required.

Monitoring

Monitor serum phosphate, liver function and ophthalmological status regularly throughout treatment.

Counselling the patient

  • Follow any low-phosphate dietary advice and take phosphate-lowering treatment as directed.
  • Report changes in vision such as blurring, flashes or floaters without delay.
  • Attend scheduled blood tests and eye checks as arranged by the team.

Evidence & guidelines

Approval was based on the FOENIX-CCA2 single-arm trial in FGFR2 fusion-positive cholangiocarcinoma.

Reference: NICE TA936; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways